Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection
Open Access
- 8 August 2018
- journal article
- Published by Springer Science and Business Media LLC in AAPS Open
- Vol. 4 (1), 6
- https://doi.org/10.1186/s41120-018-0026-0
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 39 references indexed in Scilit:
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Analytical methods for physicochemical characterization of antibody drug conjugatesmAbs, 2011
- CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune diseaseEmerging Therapeutic Targets, 2011
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast CancerClinical Cancer Research, 2010
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in MiceDiabetes, 2009
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsNature Chemical Biology, 2009
- Discovering and improving novel peptide therapeuticsCurrent Opinion in Pharmacology, 2008
- Elimination mechanisms of therapeutic monoclonal antibodiesDrug Discovery Today, 2006
- Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus MonkeysThe Journal of pharmacology and experimental therapeutics, 2005
- Filtration and reabsorption of endogenous low-molecular-weight protein in the rat kidneyKidney International, 1979